A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

por Beatty, Gregory L., Shahda, Safi, Beck, Thaddeus, Uppal, Nikhil, Cohen, Steven J., Donehower, Ross, Gabayan, Afshin Eli, Assad, Albert, Switzky, Julie, Zhen, Huiling, Von Hoff, Daniel D.
Publicado 2018

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom...

por Mesa, Ruben, Vannucchi, Alessandro M., Yacoub, Abdulraheem, Zachee, Pierre, Garg, Mamta, Lyons, Roger, Koschmieder, Steffen, Rinaldi, Ciro, Byrne, Jennifer, Hasan, Yasmin, Passamonti, Francesco, Verstovsek, Srdan, Hunter, Deborah, Jones, Mark M., Zhen, Huiling, Habr, Dany, Martino, Bruno
Publicado 2016

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

por Bekaii-Saab, Tanios S, Valle, Juan W, Cutsem, Eric Van, Rimassa, Lorenza, Furuse, Junji, Ioka, Tatsuya, Melisi, Davide, Macarulla, Teresa, Bridgewater, John, Wasan, Harpreet, Borad, Mitesh J, Abou-Alfa, Ghassan K, Jiang, Ping, Lihou, Christine F, Zhen, Huiling, Asatiani, Ekaterine, Féliz, Luis, Vogel, Arndt
Publicado 2020

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022